Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Cellectis Stocks Soar: Time to Buy?

Matt MonacoAvatar
Written by Matt Monaco Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 3/14/2025, 9:18 am ET 6 min read
Cellectis Stocks Soar: Time to Buy? Thumbnail

Rec

  1. “Cellectis S.A. to present groundbreaking gene-editing technology at the upcoming biotech conference.”
  2. “French biotech firm Cellectis reports promising results from its latest clinical trials.”
  3. “Cellectis S.A. announces the appointment of a new CEO from a major pharmaceutical company.”

Cellectis S.A. witnessed a 10.08 percent surge in stock trading on Friday, largely propelled by optimistic outcomes from its latest clinical trials, signaling strong market confidence in the company’s future prospects.

Recent Developments in Cellectis

  • Cellectis reported a substantial decline in quarterly earnings, but emphasized its collaboration with AstraZeneca in the field of CAR T and gene therapy.
  • The biopharmaceutical entity was the front-runner among European stocks, posting a 5.7% increase while trading in the US.
  • Their shares surged by 5.4% during a generally bearish trend for European stocks converted to ADRs in the US.
  • Cellectis presented a strategic ‘Smart CAR T’ method at the AACR-IO 2025, leveraging IL-2 to enhance CAR T cell efficacy for solid tumors.
  • A robust Q4 and FY 2024 financial report was made public, showcasing strong finances and partnerships, with liquidity lasting till mid-2027.

Candlestick Chart

More Breaking News

Live Update At 09:18:05 EST: On Friday, March 14, 2025 Cellectis S.A. stock [NASDAQ: CLLS] is trending up by 10.08%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview and Forecast

In the world of trading, having a strategic mindset is crucial to achieving long-term success. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” This approach emphasizes the importance of adapting swiftly to market changes, maximizing profitable opportunities, and maintaining discipline to avoid unnecessary risks. By adhering to these principles, traders can better navigate the volatility of the markets and improve their chances of sustained profitability.

Cellectis, a clinical-stage biotech firm known for its innovations in gene-editing and its focus on cell and gene therapies, recently announced its quarterly financial results. The company managed to bolster its position despite a drop in earnings by aligning strategically with AstraZeneca to push its CAR T and gene therapy programs forward. This partnership could unlock new breakthroughs in gene-edited medical treatments.

Their unique “Smart CAR T” strategy is breaking ground in treating solid tumors with reduced side effects, employing an IL-2 variant that amplifies the body’s defense mechanisms against tumors. This revolutionary technology might change the medical landscape and bolster investor confidence.

From a numbers standpoint, albeit the company’s revenue dwindled, closing figures point to a commendable $755,000 revenue with solid asset support. Metrics reflect a sharp focus on research and long-term growth. Holding vast capital and with persuasive partners, Cellectis remains a strong contender in its niche. The company’s price-to-sales ratio of 172.34 signals potential overvaluation, yet given the momentum in biotech, it could be momentary, especially with strategic partnerships in play.

Stock Insights and Volatility

Looking at the share prices, the market for CLLS has witnessed fluctuation. For instance, within the first quarter of 2025, the stock opened at $1.3 and fluctuated slightly, closing at $1.29. Additional data underscore continuous market movement which isn’t surprising given the biotech landscape’s inherent dynamism. There were notable peaks from minor gains over intraday sessions, but the broad movement remains steady.

The stock finished the period at $1.29 despite a thriving European market presence with a healthy US performance. Their advances on Wall Street hint toward potential shifts as American investors start to grasp the strategic moves made by Cellectis, especially in its alliance with AstraZeneca.

Impact of Recent Announcements

Following careful analysis, the recent surge in Cellectis’s stock price might be attributed to the announcement of advanced therapies and stronger-than-expected collaboration results. While the firm battles market volatility, its investor potential remains high as it pilots innovative solutions into the healthcare narrative.

The announcement of the upcoming investor call and expectations of more insightful disclosures could further bolster stock activity. Investors remain on edge, watching for cues as the company unveils further data from its aggressive therapeutic research programs, aimed at combatting critical health challenges.

Considering key partnerships and research endeavors, the market reacted positively. This paired with the relatively positive financial report suggests a confidence boost, which might sustain the uptick in stock price for the near term — potentially creating buying opportunities before the next wave of innovations hits the market.

Conclusion

In a world where biotech is rapidly evolving and capturing global focus, Cellectis shows unrelenting pursuit of breakthroughs, despite financial roadblocks. With strategic ties and pioneering science evident in its recent showcase, the firm holds the promise of valuable interventions. Trader sentiment remains hopeful as the assemblage of new therapies and industry collaborations are anticipated to unfold as market game-changers.

Thus, the road for Cellectis is set with myriad opportunities, and with a growth path this reinforced, traders may find themselves contemplating if holding a stake now might lock in dividends of its scientific strides later. As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” The narrative unfolds and potential continues to illuminate within the Cellectis domain.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Matt Monaco

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
He is a diligent trader and teacher in his To The Moon Report blogs and Small Cap Rockets strategy webinars. He shows up every day, and expects his students to as well. Matt is fond of trading sketchy, volatile OTC stocks with profit potential. His favorite patterns are panic dip buys and breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications